Halozyme Therapeutics Option Alert: Mar 20 $75 Calls at the Bid: 1300 vs 1499 OI

Halozyme Therapeutics Option Alert: Mar 20 $75 Calls at the Bid: 1300 @ $4.75 vs 1499 OI; Ref=$69.21

Halozyme Therapeutics Stock (NASDAQ: HALO)

Halozyme Therapeutics (NASDAQ:HALO) Stock, Quote.MetaTitle.unusual-options

Halozyme Therapeutics

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics Inc

HALO COLLECTIVE INC by HALO COLLECTIVE INC.

Halo Collective Inc

Abivax

Alkermes

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

Caris Life Sciences

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Grifols, S.A. - American Depositary Shares

Grifols

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Merus

Metsera

Nuvalent

Vaxcyte

PTC Therapeutics

Avidity Biosciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

TG Therapeutics

Prévisions Halozyme Therapeutics (HALO)

Actualités

Gains

Quote.Nav.option-chain

Orientation

Évaluations des analystes

Transactions internes

Intérêt court

Commerces gouvernementaux

Rapport sur les stocks

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Comments

Halozyme Therapeutics Options Inhabitueles

Unusual Options Activity for

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL